New cancer drug combo tested in early trial – but study stopped early
NCT ID NCT05904496
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs shrank tumors. However, the study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-30813 (a DGKζ inhibitor) and tislelizumab (an immunotherapy drug)
What this could lead to
If it works, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This was a very early (phase 1) trial, so safety and effectiveness are not yet known. The trial was terminated early, meaning results may be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601-1915, United States
-
Hospital Universitario Vall Dhebron
Barcelona, 08035, Spain
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Md Anderson Cancer Center
Houston, Texas, 77030-3907, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Next Oncology
San Antonio, Texas, 78229-6028, United States
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Start Madrid Fundacion Jimenez Diaz
Madrid, 28040, Spain